Additionally, while brain clusterin levels increase within the brain during AD progression, the levels of Abeta increase to a greater extent, resulting in a declining molar ratio between clusterin and Abeta specifically within regions of the brain with high Abeta deposition (Miners et al., 2017). The gene discussed is APP; the disease is Alzheimer disease.